Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Treasury Shares (2023 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Treasury Shares for 3 consecutive years, with $698019.0 as the latest value for Q3 2025.

  • On a quarterly basis, Treasury Shares rose 112.38% to $698019.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $698019.0, a 112.38% increase, with the full-year FY2024 number at $361997.0, up 99.8% from a year prior.
  • Treasury Shares was $698019.0 for Q3 2025 at 4D Molecular Therapeutics, down from $725101.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $748380.0 in Q1 2025 to a low of $181181.0 in Q4 2023.
  • A 3-year average of $438920.2 and a median of $345332.0 in 2024 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: skyrocketed 99.8% in 2024, then skyrocketed 256.54% in 2025.
  • 4D Molecular Therapeutics' Treasury Shares stood at $181181.0 in 2023, then soared by 99.8% to $361997.0 in 2024, then surged by 92.82% to $698019.0 in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Treasury Shares are $698019.0 (Q3 2025), $725101.0 (Q2 2025), and $748380.0 (Q1 2025).